Patent Application
20120213808
The present invention relates to a method for treating an autoimmune disease using an antigen-specific tolerogenic antigen presentation cell.
An inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a disease characterized by an impaired immune system in the intestinal tract. Although the detailed pathogenesis have not been fully clarified, one of causes is supposed to be a sensitive natural or acquired immune response to commensal bacteria, various microbial products and food (see Non-Patent Documents 1 to 3.)
Immunomodulation in the microenvironment should be steadily fine-regulated to maintain local homeostasis. Such regulation is believed to be site-specific (for example, gastrointestinal environment-specific) and to be mediated by chronic exposure to microorganisms. A dendritic cell serves an important role in controlling the immunomodulation (see Non-patent Document 4). The dendritic cell is the most powerful and effective antigen presentation cell and is important in induction of an early immune response. The dendritic cell also plays a key role in producing immunological tolerance. It has been reported that the dendritic cell in situ induces antigen-specific immunological tolerance in the central and peripheral lymphoid organs (see Non-Patent Document 5). Although the immunological tolerance mechanism has not been completely understood, it has been reported that the dendritic cell promotes the differentiation of a CD4+CD25− T cell into a CD4+CD25+Foxp3+ regulatory T cell to induce the immunological tolerance by T cell at the periphery (see Non-Patent Document 6).
Selective enhancement of the immunological tolerogenicity by the dendritic cell has been performed using an immature dendritic cell prepared by pharmacological inhibition of maturation or a recombinant dendritic cell expressing an immunosuppressive molecule (see Non-Patent Document 7). It has been also reported that in studies using mouse models, some types of the tolerogenic or regulatory dendritic cells antigen-specifically improve a pathological condition in a wide variety of diseases, such as an autoimmunity, allergy, transplant rejection and the like (see Non-Patent Documents 6 and 8 to 11).
Cecal bacterial antigen (hereinafter referred to as “CBA”) is one of possible substances associated with a pathological condition of the inflammatory bowel disease. It has been reported that a mouse model of severe combined immunodeficiency develops severe enteritis when transplanted with CBA-responsive interleukin (IL)-17 producing CD4+T cells (see Non-Patent Documents 12 to 14). Although CBA is considered to be composed of some proteins, there are no reports of identification of the protein which acts as antigen specific to the inflammatory bowel disease.
Non-Patent Document 1:
Non-Patent Document 3:
Non-Patent Document 4:
Non-Patent Document 5:
Non-Patent Document 6:
Non-Patent Document 7:
Non-Patent Document 8:
Non-Patent Document 9:
Non-Patent Document 10:
Non-Patent Document 11:
Non-Patent Document 12:
Non-Patent Document 13:
C. O. Elson et al., Gastroenterology, 132: 2359-70 (2007)
Non-Patent Document 14:
The inflammatory bowel disease has not effectively treated based on the existing treatment strategies, and thus there has been a need for a novel and better treatment method.
The inventors of the present invention revealed that carbonic anhydrase I (i.e., CA I) and a CA I-pulsed regulatory dendritic cell have an antigen-specific therapeutic effect on inflammatory bowel disease in a model mouse, and thus completed the present invention. Specifically, by two-dimensional difference gel electrophoresis (2D-DIGE) and time-of-flight mass spectrometry (TOF-MS), a primary protein of CBA was analyzed and identified to be CA I. Then, the identified CA I pulsed regulatory dendritic cells were revealed to induce an antigen-specific depressant effect on enteritis in a colitis model mouse. Also, the inventors found that direct administration of CA I induced the antigen-specific depressant effect on enteritis in the colitis model mouse.
Accordingly, the present invention is directed to a method for treatment of an autoimmune disease using an antigen-specific tolerogenic antigen presentation cell, and in particular, a method for treatment of autoimmune disease (particularly, an inflammatory bowel disease), comprising producing the antigen-specific tolerogenic antigen presentation cell by using CA I as an antigen.
More specifically, the present invention is directed to the following inventions:
(1) A pharmaceutical composition for use in treatment or prevention of an autoimmune disease, comprising CA I as an active ingredient;
(2) The pharmaceutical composition of (1), wherein the treatment or prevention of the autoimmune disease is cell therapy based on tolerogenic antigen presentation cell;
(3) The pharmaceutical composition of (2), wherein the tolerogenic antigen presentation cell is a regulatory dendritic cell;
(4) The pharmaceutical composition of any one of (1) to (3), wherein the autoimmune disease is inflammatory bowel disease;
(5) A pharmaceutical composition for use in treatment or prevention of an autoimmune disease, comprising a CA I-specific tolerogenic antigen presentation cell as an active ingredient;
(6) The pharmaceutical composition of (5), wherein the tolerogenic antigen presentation cell is a regulatory dendritic cell;
(7) A pharmaceutical composition for use in treatment or prevention of an autoimmune disease, comprising a CA I-specific regulatory T cell as an active ingredient;
(8) The pharmaceutical composition of any one of (5) to (7), wherein the autoimmune disease is inflammatory bowel disease;
(9) A composition for use in preparation of an antigen-specific tolerogenic antigen presentation cell, comprising CA I;
(10) The composition of (9), wherein the tolerogenic antigen presentation cell is a regulatory dendritic cell;
(11) A method for inducing immune tolerance in a patient, comprising using CA I;
(12) The method of (11), which is based on a tolerogenic antigen presentation cell;
(13) the method of (12), wherein the tolerogenic antigen presentation cell is a regulatory dendritic cell;
(14) the method of any one of (11) to (13), comprising a step of pulsing the tolerogenic antigen presentation cell with CA I;
(15) The method of any one of (11) to (14), comprising:
a step of obtaining the tolerogenic antigen presentation cell from the patient;
a step of pulsing the tolerogenic antigen presentation cell with CA I; and
a step of administering the pulsed tolerogenic antigen presentation cell into the patient;
(16) The method according to any one of (11) to (13), including a step of administering CA I into the patient;
(17) A method for treating or preventing an autoimmune disease, comprising using CA I;
(18) The method of (17), which is based on a tolerogenic antigen presentation cell;
(19) The method of (17) or (18), wherein the tolerogenic antigen presentation cell is a regulatory dendritic cell;
(20) The method according to any one of (17) to (19), comprising a step of pulsing the tolerogenic antigen presentation cell with CA I;
(21) The method according to any one of (17) to (20), comprising:
a step of obtaining the tolerogenic antigen presentation cell from a patient;
a step of pulsing the tolerogenic antigen presentation cell with CA I; and
a step of administering the pulsed tolerogenic antigen presentation cell into the patient;
(22) The method according to any one of (17) to (19), comprising a step of administering CA I into a patient;
(23) The method according to any one of (17) to (22), wherein the autoimmune disease is inflammatory bowel disease;
(24) a method for producing an antigen-specific tolerogenic antigen presentation cell, comprising using CA I;
(25) The method of (24), comprising:
a step of preparing the tolerogenic antigen presentation cell; and
a step of pulsing the tolerogenic antigen presentation cell with CA I;
(26) The method of (24) or (25), wherein the tolerogenic antigen presentation cell is a regulatory dendritic cell;
(27) The method according to any one of (24) to (26), wherein the antigen-specific tolerogenic antigen presentation cell is for use in induction of immunological tolerance, or in treatment or prevention of an autoimmune disease;
(28) The method of (27), wherein the autoimmune disease is inflammatory bowel disease;
(29) A method for producing an antigen-specific regulatory T cell, comprising using CA I;
(30) The method of (29), comprising:
a step of preparing a tolerogenic antigen presentation cell and a naive T cell;
a step of pulsing the tolerogenic antigen presentation cell with CA I; and
a step of contacting the pulsed tolerogenic antigen presentation cell with the naive T cell;
(31) The method of (29) or (30), wherein the tolerogenic antigen presentation cell is a regulatory dendritic cell;
(32) The method according to any one of (29) to (31), wherein the antigen-specific regulatory T cell is for use in induction of immunological tolerance, or in treatment or prevention of an autoimmune disease;
(33) The method of (32), wherein the autoimmune disease is inflammatory bowel disease;
(34) A CA I-specific immunogenic antigen presentation cell;
(35) The cell of (34), wherein the immunogenic antigen presentation cell is a regulatory dendritic cell; and
(36) A CA I-specific regulatory T cell.
The term “cell therapy” herein means a method of treatment of diseases, characterized by administration of a cell. The cell may be derived from a patient to be administered, or may be derived from another individual. Preferably, the cell derived from a patient to be administered is used. In general, the cell therapy comprises a step of obtaining and isolating cells, a step of treating the cells and a step of administering the treated cells into the patient. The cell therapy may further comprise a step of proliferating the cell. The phrase “a cell therapy based on a tolerogenic antigen presentation cell” means a method of treatment of diseases, characterized by administration of the tolerogenic antigen presentation cell.
Generally, “carbonic anhydrase I (CA I)” is a metalloenzyme which is present in cytoplasm and reversibly catalyzes a hydration reaction of carbon dioxide. As used herein, the “CA I” does not have to be a full-length CA I and may also include its partial peptide as long as it is able to induce the CA I-specific immunogenic antigen presentation cell. Further, as used in this specification, the CA I (including its partial peptide; the same shall apply hereinafter) may be modified by substituting, deleting, adding and/or inserting a part (for example, a few) of amino acid sequence as long as it is able to induce the CA I-specific immunogenic antigen presentation cell. Also, as used in this specification, the CA I may be consisted of the amino acid sequence with homology of 50% or more, 60% or more, 75% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence of CA I as long as it is able to induce the CA I-specific immunogenic antigen presentation cell. Alternatively, as used herein, the CA I may be a protein encoded by a genome sequence which can hybridize with the genome sequence of CA I under a stringent condition (Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989)) as long as it is able to induce the CA I-specific immunogenic antigen presentation cell. The CA I may be appropriately modified to improve ability to induce immunological tolerance. The CA I may also be a fused protein with a substance which improves ability to induce immunological tolerance, or with a substance with ability to induce immunological tolerance. Preferably, the CA I may be a protein or a peptide included in above said CA I of the present specification, wherein an immunogenic antigen presentation cell induced by the protein or the peptide can produce immunological tolerance and can treat or prevent autoimmune disease (preferably inflammatory bowel disease).
The term “a tolerogenic antigen presentation cell” refers to the antigen presentation cell which can induce immunological tolerance. The tolerogenic antigen presentation cell may be a cell obtained from a patient which is subjected to be treated, or a cell obtained from those other than the patient, and preferably is the cell obtained from the patient. The tolerogenic antigen presentation cell may include, for example, a regulatory dendritic cell. The “regulatory dendritic cell” is not particularly limited as long as it is a subset of the dendritic cell involved in the immunological tolerance, which may be also referred to as a tolerogenic dendritic cell. The regulatory dendritic cell may encompass a dendritic cell having ability to induce immunosuppression through the production of cytokine such as interleukin 10, a dendritic cell having ability to generate a regulatory T cell (for example, a CD4+CD25+Foxp3+ regulatory T cell) and/or a dendritic cell having ability to control the function of the T cell. For example, the regulatory dendritic cell may include a dendritic cell without expressing costimulatory molecules, such as CD40, CD80 and CD86, on its surface; and a dendritic cell expressing CCR9 on its surface (H. Hadeiba et al., Nat. Immunol., 9(11): 1253-60 (2008)); a dendritic cell expressing miR-155 on its surface (A. W. Pedersen et al., Clin. Exp. Immunol., 157(1): 48-59 (2009)); and a dendritic cell expressing CD200 receptor 3 on its surface (K. Sato et al., Blood., 1173: 4780-9 (2009)).
The term “regulatory T cell” refers to a T cell having a role to inhibit activity of another T cell with the ability to damage tissue. The regulatory T cell may be a cell obtained from a patient who is subjected to be treated, or a cell obtained from those other than the patient, and preferably is the cell obtained from the patient. More preferably, the regulatory T cell is a T cell expressing Foxp3, CD4 and CD25 molecules on its surface.
The term “a naive T cell” refers to a T cell which has not contacted with the specific antigen, and preferably is CD4+CD25− naive T cell.
The term “immunological tolerance” means decrease in immune response level, delay in occurrence or progress of immune reaction and/or the decrease in risk from immune reaction. The term antigen-specific immunological tolerance means the immunological tolerance produced especially to a given antigen, compared with the other antigen.
As used herein, the term “an autoimmune disease” refers to a disease developed by occurrence of immune response to a self-antigen. In the present invention, the autoimmune disease includes inflammatory bowel disease. The term “inflammatory bowel disease” refers to a disease characterized by chronic persistent enteritis, and includes ulcerative colitis, Crohn's disease and the like.
Since the cell therapy using CA I as the antigen according to the present invention can improve symptom in autoimmune disease, especially the symptom in inflammatory bowel disease, it is useful in a method for treating or preventing autoimmune disease, which has been difficult to treat.
CA I may be prepared by appropriately designing a primer with reference to the gene sequence information well known to those skilled in the art (for example, the gene sequence of mouse CA I is shown as SEQ ID No. 1, and the gene sequence of human CA I is shown as SEQ ID No. 3), generating an expression vector and transforming the vector into Bacillus coli, fermentum, insect cells, animal cells and the like to induce the expression of the CA I. Alternatively, CA I may be also prepared employing cell free protein synthesis system using wheat germ ribosomal RNA (K. Madin et al., Proc. Natl. Acad. Sci. USA, 97: 559-64 (2000)).
In using a partial peptide of CA I as the CA I, it may be prepared by method for amino acid synthesis which is well known to those skilled in the art. For instance, the partial peptide of the CA I may be prepared by using chemical synthesis method, such as Fmoc method or Boc method, or by using an automated peptide synthesizer. Such peptide synthesizer includes, for example, PSSM-8 (Shimadzu Corporation); model 433A Peptide Synthesizer (Applied Biosystems, Inc.); ACT396Apex (Advanced ChemTech Inc.) and the like.
Introduction of mutation into the CA I (including its partial peptide) may be performed using the technique well known to those skilled in the art, such as site-specific mutagenesis.
“The method for inducing immune tolerance in a patient, comprising (characterized by) using CA I” according to the present invention encompasses a method for inducing immune tolerance, comprising direct administration of CA I into the patient, and a method for inducing immune tolerance, comprising ex vivo pulse of a tolerogenic antigen presentation cell by CA I.
“The method for treating or preventing an autoimmune disease, comprising (8 characterized by) using CA I” according to the present invention encompasses a method for treating or preventing an autoimmune disease, comprising direct administration of CA I into the patient, and a method for treating or preventing an autoimmune disease, comprising ex vivo pulse of a tolerogenic antigen presentation cell by CA I.
In the present invention, CA I or a pharmaceutical composition comprising CA I as an active ingredient into a patient may be directly administered via routes, such as oral, nasal, intratracheal, subcutaneous, intravascular (i.e., intravenous) routes and the like. Most preferable administration route is oral administration. A drug formulation for the composition may include, for example, an injection, capsule, tablet, syrup, granule, powder-fog agent and the like. The administration is not particularly limited as long as the desirable therapeutic or preventive effect can be obtained. Most preferable administration is oral administration. Further, the administration may be performed temporarily, or continuously or intermittently. For instance, the administration frequency may be selected from, for example, single administration, once to 4 times a week, and intermittent dosing such as once a month to every three months. A dosage is not particularly limited as long as the desirable therapeutic or preventive effect can be obtained, and may be appropriately determined depending on a symptom, sex, age and the like. Further, the dosage may be determined based on, for example, a yield of the antigen-specific tolerogenic antigen presentation cells or antigen-specific regulatory T cells, or degree of therapeutic or preventive effect on the autoimmune disease. For instance, a dosage of the antigen may be 0.01 ng/kg to 10 mg/kg, preferably 0.1 ng/kg to 1 mg/kg, more preferably 0.5 ng/kg to 100 μg/kg, and the most preferably 1 ng/kg to 10 μg/kg. Furthermore, CA I may be administered together with other pharmaceutical agents including an immunosuppressive agent such as cyclosporine and tacrolimus and the like. For example, CA I and such other pharmaceuticals may be administered at once, or separately at an interval.
The above method for inducing immune tolerance, comprising ex vivo pulse of tolerogenic antigen presentation cell by CA I may be performed, for example, by the following steps:
a step of preparing tolerogenic antigen presentation cell;
a step of pulsing the tolerogenic antigen presentation cell by CA I; and
a step of administering the pulsed tolerogenic antigen presentation cell into a patient who is subjected to be induced immunological tolerance.
Preferably, the method for inducing immune tolerance, comprising ex vivo pulse of the tolerogenic antigen presentation cell by CA I according to the present invention may also be performed, for example, by the following steps:
a step of preparing a patient-derived regulatory dendritic cell;
a step of pulsing the regulatory dendritic cell by CA I; and
a step of administering the pulsed regulatory dendritic cell into the patient who is subjected to be induced immunological tolerance induction.
The method for treating or preventing an autoimmune disease, comprising ex vivo pulse of the tolerogenic antigen presentation cell by CA I may be performed, for example, by the following steps:
a step of preparing the tolerogenic antigen presentation cell;
a step of pulsing the tolerogenic antigen presentation cell by CA I; and
a step of administering the pulsed tolerogenic antigen presentation cell into the patient of autoimmune disease.
Preferably, the method for treating or preventing an autoimmune disease, comprising ex vivo pulse of tolerogenic antigen presentation cell by CA I may also be performed by the following steps:
a step of preparing a patient-derived regulatory dendritic cell;
a step of pulsing the regulatory dendritic cell by CA I; and
a step of administering the pulsed regulatory dendritic cell into the patient of autoimmune disease.
The regulatory dendritic cell, which is one of the tolerogenic antigen presentation cell, may be prepared by taking bone marrow cells form the patient, incubating the cells in presence of GM-CSF, IL-10 and a human transforming growth factor-β1 (TGF-β1) for 8 days and then stimulating the cells in the presence of an ultrapure LPS for 24 hours. Alternatively, the regulatory dendritic cell may be prepared by taking a peripheral blood, isolating and collecting a fraction of mononuclear cells using methods well known to those skilled in the art, incubating the cells in the presence of GM-CSF, IL-10 and a human transforming growth factor-β1 (TGF-β1) for 8 days and then stimulating the cells in the presence of the ultrapure LPS for 24 hours. The resulting regulatory dendritic cell may be further purified by removing dendritic cells expressing costimulatory molecules.
Pulse of the tolerogenic antigen presentation cell by CA I may be performed by incubating the tolerogenic antigen presentation cells in the presence of CA I.
Administration of the pulsed tolerogenic antigen presentation cell into the patient may be performed using well known technique to those skilled in the art as cell therapy employing immunocyte. For example, the cell may be administered into the blood vessel (the intravenous). The administration may be performed at once, or continuously or intermittently. For instance, the administration may be performed preferably as single administration or once to 4 times a week, and more preferably as single administration or once a week. The intermittent administration, such as once a month to every three months, may be also employed. A dose is not particularly limited as long as the desirable therapeutic or preventive effect can be obtained, and may be appropriately determined depending on a symptom, sex, age and the like. The dose may be determined based on, for example, degree of the immunological tolerance, number of the antigen-specific regulatory dendritic cell and/or the regulatory T cell, or degree of the therapeutic or preventive effect on the autoimmune disease. For instance, a dose of the cells may be 1×106 cells to 1×1010 cells, preferably 1×107 cells to 1×109 cells, more preferably 5×107 cells to 5×108 cells, most preferably 1×108 cells. The pulsed tolerogenic antigen presentation cell may be administered together with other pharmaceuticals, including an immunosuppressive agent such as cyclosporine and tacrolimus and the like. For example, the cells and such other pharmaceuticals may be administered at once, or separately at an interval.
The method for inducing immune tolerance, comprising ex vivo pulse of the tolerogenic antigen presentation cell by CA I, and the method for treating or preventing an autoimmune disease, comprising ex vivo pulse of the tolerogenic antigen presentation cell by CA I may further comprise a step of include ex vivo inducing the CA I-specific regulatory T cells ex vivo.
The method for inducing immune tolerance, comprising ex vivo pulse of the tolerogenic antigen presentation cell by CA I may be performed, for example, by the following steps:
a step of preparing tolerogenic antigen presentation cells and naive T cells;
a step of pulsing the tolerogenic antigen presentation cells by CA I;
a stop of contacting the pulsed tolerogenic antigen presentation cells with the naive T cells to induce the regulatory T cells; and
a step of administering the induced regulatory T cells into the patient who is subjected to induce immunological tolerance.
Preferably, the method for inducing immune tolerance, comprising ex vivo pulse of the tolerogenic antigen presentation cell by CA I may be performed, for example, by the following steps:
a step of preparing a patient-derived regulatory dendritic cells and naive T cells;
a step of pulsing the regulatory dendritic cells by CA I; and
a step of contacting the pulsed regulatory dendritic cells with the naive T cells to induce the regulatory T cells; and
a step of administering the induced regulatory T cells into the patient who is subjected to induce immunological tolerance.
The method for treating or preventing an autoimmune disease, comprising ex vivo pulse of the tolerogenic antigen presentation cells by CA I may be performed, for example, by the following steps:
a step of preparing tolerogenic antigen presentation cells and a naive T cells;
a step of pulsing the tolerogenic antigen presentation cells by CA I;
a step of contacting the pulsed tolerogenic antigen presentation cells with the naive T cells to induce the regulatory T cells; and
a step of administering the induced regulatory T cells into the patient of autoimmune disease.
Preferably, the method for treating or preventing an autoimmune disease, comprising ex vivo pulse of the tolerogenic antigen presentation cells by CA I may be performed by the following steps:
a step of preparing patient-derived regulatory dendritic cells and naive T cells;
a step of pulsing the regulatory dendritic cells by CA I;
a step of contacting the pulsed regulatory dendritic cells with the naive T cells to induce the regulatory T cells; and
a step of administering the induced regulatory T cells into the patient of autoimmune disease.
Said naive T cell may be isolated from peripheral blood or spleen cells with a CD4+CD25+ regulatory T cell Isolation Kit and AutoMACS (Miltenyi Biotec GmbH) according to the manufacturer's protocols. Purity of the naive T cells may be identified by FACS analysis using peridinin chlorophyll protein (PerCP) labeled anti-CD4 monoclonal antibody and phycoerythrin (PE) labeled anti-CD25 monoclonal antibody.
The induction of regulatory T cells by pulsed regulatory dendritic cells may be achieved, for example, by incubating 5×106 of naive T cells together with 5×105 of regulatory dendritic cells in 1 mL of RPMI medium for 7 days.
The administration of the induced regulatory T cells into the patient may be performed similarly to the above-described administration of the pulsed tolerogenic antigen presentation cells into the patient.
“The pharmaceutical composition for use in treatment or prevention of autoimmune disease, comprising CA I as an active ingredient” of the present invention may be a composition which is directly administered into a patient to induce immunological tolerance, or may be a composition used to prepare the antigen-specific tolerogenic antigen presentation cells ex vivo. When the composition is used to prepare the antigen-specific tolerogenic antigen presentation cells, the resulting tolerogenic antigen presentation cells or the regulatory T cells stimulated by such antigen presentation cells can be administered into the patient in accordance with the above described methods.
“The pharmaceutical composition for use in treatment or prevention of an autoimmune disease, comprising CA I-specific tolerogenic antigen presentation cells as an active ingredient” may be a composition which is directly administered into the patient to induce immunological tolerance, or may be a composition which is used to prepare the antigen-specific regulatory T cells ex vivo. The CA I-specific tolerogenic antigen presentation cell may be provided by preparing tolerogenic antigen presentation cells and then pulsing the tolerogenic antigen presentation cells by CA I in accordance with the above described methods. The resulting tolerogenic antigen presentation cells or the regulatory T cells stimulated by such antigen presentation cell may be administered into the patient in accordance with the above described methods.
“The pharmaceutical composition for use in treatment or prevention of autoimmune disease, comprising CA I-specific regulatory T cells as an active ingredient” may be a composition which is directly administered into the patient to induce immunological tolerance. The CA I-specific regulatory T cells may be provided by taking tolerogenic antigen presentation cells and the naive T cells, pulsing the tolerogenic antigen presentation cells by CA I and then contacting the pulsed tolerogenic antigen presentation cells with the naive T cells. The resulting regulatory T cell may be administered into the patient in accordance with the above described methods.
For the present invention, the composition comprising CA I may appropriately contain additives such as a stabilizing agent (see, for example, “Pharmaceutical Excipients Dictionary” Yakuji Nippo Limited., and “Handbook of Pharmaceutical Excipients” APhA Publications), in addition to CA I. It may also contain other pharmaceuticals, including an immunosuppressive agent such as cyclosporine, tacrolimus and the like. In the present invention, the composition comprising tolerogenic antigen presentation cells or regulatory T cells may appropriately further contain suitable additives for the cell therapy, in addition to the tolerogenic antigen presentation cells or the regulatory T cells.
Following examples illustrate certain aspects of the invention in greater detail but not intended to limit the scope of the invention in any way. All documents cited in the present application are incorporated herein by reference in their entirety. The patent application claims priority to Japanese Patent Application No. 2009-242491, the content of which are incorporated herein by reference in its entirety.
[Statistical Analysis]
For all of individual experiments, data was reported in an average value±SD. The data was examined by Student's t-test or Mann-Whitney's U test. The statistical significance was defined as P<0.05. Statistic calculation was performed using StatView version 5.0 Statistical Program.
In all of following experiments, a C.B-17 SCID mouse mated under the specific pathogen-free condition and a BALB/c (H-2d) female mouse were employed (CLEA Japan, Inc., Tokyo, Japan). All of the mice were 8 to 12-week-old and were maintained by feeding conventional laboratory animal feed at 22° C. and 55% relative humidity in a cycle of 12 hours light and 12 hours darkness. All animals bred according to Good Laboratory Practice Guidelines. This study was performed with approval from Laboratory Animal Care Committee of Ehime University.
(2) Preparation of Dendritic Cell
The mature dendritic cells were prepared by incubating 2×106 of bone-marrow cells taken from the BALB/c mouse in the presence of 20 ng/mL of mouse granulocyte macrophage-colony stimulating factor (GM-CSF) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) for 8 days and then stimulating them in the presence of 1 μg/mL of the ultrapure LPS (InvivoGen, San Diego, Calif., US) for 24 hours.
The regulatory dendritic cells were prepared by incubating 2×106 of bone-marrow cells taken from the BALB/c mouse in the presence of 20 ng/mL of mouse GM-CSF (Wako Pure Chemical Industries, Ltd.), mouse interleukin-10 (IL-10) (Wako Pure Chemical Industries, Ltd.) and human transforming growth factor-β1 (TGF-β1) (Wako Pure Chemical Industries, Ltd.) for 8 days and then stimulating them in the presence of 1 μg/mL of the ultrapure LPS (InvivoGen) for 24 hours. Next, the regulatory dendritic cells were stained with a fluorescein isothiocyanate (FITC) labeled anti-CD40 monoclonal antibody (Clone 3/23, BD Biosciences Pharmingen, San Diego, Calif., US), an anti-CD80 monoclonal antibody (Clone 16-10AI, BD Biosciences Pharmingen) and an anti-CD86 monoclonal antibody (Clone GL1, BD Biosciences Pharmingen) at 4° C. for 30 minutes. The stained cells were labeled with anti-FITC microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), and then, the CD40+CD80+CD86+ cell (approximately 20% of the total cells prepared) was eliminated with AutoMACS (Miltenyi Biotec GmbH) to remove the dendritic cell expressing a costimulatory molecule.
(3) Detection of Dendritic Cell Maker
The dendritic cells were washed and then resuspended into a solution of 1% FBS and 0.2% sodium azide in PBS. After blocking its Fc receptor by a purified rat anti-mouse CD16/CD32 monoclonal antibody (Clone 2.4G2, BD Pharmingen), the dendritic cells were stained with a FITC labeled anti-CD11c monoclonal antibody (Clone HL3, BD Pharmingen), an anti-CD80 monoclonal antibody, an anti-CD86 monoclonal antibody and an anti-CD40 monoclonal antibody, a PE labeled anti-I-A/I-E monoclonal antibody (Clone 2G9, BD Pharmingen) and an anti-H-2Kd monoclonal antibody (Clone AMS-32.1, BD Pharmingen) in a dark room at 4° C. for 30 minutes. An isotype-matched monoclonal antibody was used as a control. The fluorescence staining was examined by the flow cytometry analysis.
(4) Results
The results are shown in
The 2×105 cells of dendritic cells prepared as described in Example 1 were incubated in the presence of 1 pg/mL of polyinosinic-polycytidylic acid (polyl:C) (Sigma Chemical Co., St. Louis, Mo., US), 1 μg/mL of ultrapure LPS, 1 μg/mL of R848 (InvivoGen) or cytosine-phosphorothiolate-guanine oligonucleotide (CpG-ODN) (TCCATGACGTTCCTGATGCT: SEQ ID No. 5) in 200 μL of RPMI1640 medium (10% fetal bovine serum (FCS), 20 mM of HEPES, 2-mercaptoethanol, penicillin and streptomycin in RPMI-1640 medium) in a round-bottom 96-well plate for 24 hours. The IL-10 and IL-6 in the supernatant were determined using a Cytometric Bead Array Kit (BD Biosciences Pharmingen) in accordance with the manufacturer's protocols.
The results are shown in
It has been understood that Foxp3+CD4+CD25+regulatory T cell plays a key role in modulation of various immune responses (J. D. Fontenot et al., Nat. Immunol., 6: 331-7 (2005); D. A. Vignali et al., Nat. Rev. Immunol., 8: 523-32 (2008); S. Hori et al., Science, 299: 1057-61 (2003)). It has been reported that regulatory dendritic cells and immunotolerogenic dendritic cells induce expression of Foxp3+CD4+CD25+regulatory T cells and play a role in induction of tolerogenesis in mouse and human (S. Fujita et al., Blood, 110: 3793-803 (2007); M. Torisu et al., J. Gastroenterol., 43: 100-7 (2008); I. E. Dumitriu et al., J. Immunol., 182: 2795-807 (2009)). Therefore, it was examined whether the regulatory dendritic cells induce expression of Foxp3+CD4+CD25+ regulatory T cells or not.
(1) Purification of CD4+CD25− T Cells
CD4+CD25− T cells were isolated from spleen cells of BALB/c mouse with CD4+CD25+ regulatory T cell Isolation Kit and AutoMACS (Miltenyi Biotec GmbH) in accordance with the manufacturer's protocol. The purity of the isolated cells were confirmed to be 98% or more by the FACS analysis using a peridinin-chlorophyll-protein (PerCP) labeled anti-CD4 monoclonal antibody (BD Pharmingen) and a phycoerythrin (PE) labeled anti-CD25 monoclonal antibody (Miltenyi Biotec GmbH).
(2) In Vitro induction of Foxp3+CD4+CD25+ T Cells
5×106 of CD4+CD25− T cells isolated from BALB/c mouse was incubated together with 5×105 of mature dendritic cells or regulatory dendritic cells isolated from BALB/c mouse in 1 mL of RPMI medium using a 35×10 mm-type cell culture dish (Cornig Inc., Horseheads, NY, US) for 7 days. After the incubation, the cells were stained with PE labeled anti-Foxp3 monoclonal antibody (Clone FJK-16s, eBioscience, Inc., San Diego, Calif., US), allophycocyanin (APC) labeled anti-CD25 monoclonal antibody (Clone PC61, BD Pharmingen) and PerPC labeled anti-CD4 monoclonal antibody (Clone RM4-5, BD Pharmingen) in accordance with the manufacturer's protocol. The fluorescence staining was examined by flow cytometry analysis using FloJo software.
(3) Results
Results are shown in
A therapeutic effect of the administration of regulatory dendritic cells on colitis was examined by following method:
CBA was prepared according to the procedure which had been previously reported (Y. Cong et al., J. Exp. Med., 187: 855-64 (1998)). BALB/c mice were euthanized to extract its appendixes. Five appendixes were incised and added to 10 mL of phosphate buffered saline (PBS) containing 1.0 mm Silica-Sepharose (Lysing Matrix C, MP Biomedicals, Sorong, Ohio, US). After stirring for 5 minutes, the mixture was centrifuged at 5,000 g for 5 minutes at 4° C. to remove Silica-Sepharose and undissolved cells. Subsequently, the supernatant was centrifuged at 18,000 g for 30 minutes at 4° C., and the lysate was sterilized with a syringe filter with pore size 0.2 μm. The protein concentration of the lysate was determined using a DC Protein Assay Kit (Bio-Rad Laboratories Inc., Hercules, Calif., US).
(2) Preparation of CBA- or KLH-Pulsed Regulatory Dendritic Cell
The regulatory dendritic cells prepared as described in Example 1 were pulsed with either 50 μg/mL of CBA or 50 μg/mL of keyhole-limpet-hemocyanin (KLH) (Thermo Scientific, Rockford, Ill., US) for 24 hours to induce CBA-pulsed dendritic cells (Reg-DCsCBA) or KLH-pulsed dendritic cells (Reg-DCsKLH), respectively.
(3) Preparation of Enteritis Model and its Treatment with Dendritic Cells
An enteritis model was prepared according to the procedure which had been previously reported (S. Kjellev et al., Int. Immunopharmacol., 6: 1341-54 (2006)). CD4+CD25− T cells obtained from BALB/c mice were suspended in PBS to be 3×105 cells/0.2 mL/mouse and then transplanted into a C.B-17 SCID mouse by the intraperitoneal administration. The day of transplantation was set as day 0. CD4+CD25− T cell-nontransplanted mice were used as a control group (n=6). On day 0, with the CD4+CD25− T cells, regulatory dendritic cells (n=7), Reg-DCsKLH (n=6) or Reg-DCsCBA (n=8), all of which had been obtained from the BALB/c mouse, were suspended in PBS to be 1×106 cells/0.2 mL/mouse and were administered intraperitoneally. Mice which were administered with 0.2 mL PBS instead of the dendritic cells was used as a PBS group (n=10). The mice were weighed every week. The mice were euthanized 4 weeks after the cell transplantation to measure a length of colons.
(4) Histological Evaluation of Colitis
The mice were euthanized 4 weeks after the cell transplantation and colons were taken from the mice. A transverse colon was extracted from the colon, fixed in 10% neutral buffered formalin and embedded in paraffin. The tissue section of the colon was stained by H&E or a periodic acid-Schiff reagent (PAS). A degree of inflammation in the tissue section was determined according to the procedure which has been previously reported (S. Kjellev et al., Int. Immunopharmacol., 6: 1341-54 (2006)). The histological picture was scored according to the following criteria: 1) severity of inflammation: 0 none; 1 mild lymphocyte infiltration; 2 moderate lymphocyte infiltration or local crypt degeneration; 3 severe inflammation or plural crypt degeneration, and/or expression of erosion; 2) degree of inflammation: 0 none; 1 mucosal membrane; 2 submucosal layer; 3 transmural; 3) mucous amount: 0 normal; 1 slightly reduced; 2 moderately reduced or local absence; 3 severely reduced; 4 complete absence; and 4) degree of epithelial cell proliferation: 0 none; 1 mild increase in number of cells or crypt length; 2 moderate or locally significant increase; 3 significant increase—in entire portion of the tissue section. The histological score was determined as the sum of the above four individual parameters.
(5) Results
The results are shown in
The histological score was determined on the basis of the severity of inflammation, the degree of inflammatory cell infiltration, the mucous amount and the degree of epithelial cell proliferation. The mouse which was administrated with Reg-DCsCBA indicated significantly lower histological score than the mouse which was administered with PBS (
(1) Measurement of Expression of Inflammatory Cytokine mRNA
Each of four CD4+CD25− T cells transplanted mice were administered with Reg-DCsCBA or PBS as described in Example 4, and transverse colons were taken from said mice and were homogenized on a TissueLyser (QIAGEN K.K., Tokyo, Japan). All RNAs were extracted using RNeasy Plus MiniKit (QIAGEN K.K.). A complementary DNA (cDNA) was prepared from 10 μg of RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Inc., Foster City, Calif., US). The mRNA expression of IL-10, IL-6 and IL-17A in the colon taken from the enteritis model mouse was measured with real time RT-PCR, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used as a control. A relative expression level was calculated according to the procedure which had been previously reported (Y. Tokumoto et al., J. Med. Virol., 79: 1120-7 (2007)).
(2) Measurement of Production Quantity of Inflammatory Cytokine in Ex Vivo Cultured Colon
A 1 cm-tissue section was cut from the transverse colon, washed to remove feces, and washed with a sterile PBS three times. This section of the colon was added into the RPMI1640 medium (RPMI1640 medium containing 10% FCS, 20 mM HEPES, 2-mercaptoethanol, penicillin and streptomycin) and incubated at 37° C. 5% CO2. The supernatant was collected 3 days after the start of incubation. Expressions of IL-17, IL-10, IL-6 tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in the supernatant were measured with ELISA Kit (R&D Systems Company, Minneapolis, Minn., U.S.A) and Cytometric Bead Array Kit (BD Biosciences Pharmingen).
Analysis of the cytokine mRNA expression revealed that in the colon of the mouse which was administered with Reg-DCsCBA, both expression levels of IL-6 and IL-17A were decreased, and expression level of IL-10 was increased (
In order to demonstrate the mechanism of enteritis suppression by Reg-DCsCBA, transcription factor and cytokine in the mesenteric lymph nodes (MLN) cell were measured.
(1) Measurement of mRNA Expression of Transcription Factor
The CD4+CD25− T cells transplanted mouse was administered with Reg-DCsCBA or PBS as described in Example 4, and MLN cells were taken from said mouse and were homogenized on the TissueLyser (QIAGEN K.K.). All RNAs were extracted using RNeasy Plus MiniKit (QIAGEN K.K.). A complementary DNA (cDNA) was prepared from 10 μg of RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Inc.) The mRNA expression of Foxp3 and retinoic acid-based orphan receptor gamma t (RORγ T) in the MLN cells taken from the enteritis model mouse was measured with real time RT-PCR, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used as a control. A relative expression level was calculated according to the procedure which had been previously reported (Y. Tokumoto et al., J. Med. Virol., 79: 1120-7 (2007)).
(2) Measurement of mRNA Expression of Inflammatory Cytokine
The CD4+CD25− T cells transplanted mouse was administered with Reg-DCsCBA or PBS as described in Example 4, and MLN cells were taken from said mouse and were homogenized on the TissueLyser (QIAGEN K.K.). All RNAs were extracted using RNeasy Plus MiniKit (QIAGEN K.K.). A complementary DNA (cDNA) was prepared from 10 μg of RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Inc.). The mRNA expression of IL-17A, IL-6, IL-10 and TGF-β in the MLN cells taken from the colitis mouse model was measured with real time RT-PCR, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression as a control. A relative expression level was calculated according to the procedure which had been previously reported (Y. Tokumoto et al., J. Med. Virol., 79: 1120-7 (2007)).
(3) Measurement of Production Quantity of Inflammatory Cytokine by ELISA
1×106 MLN cells taken from the CD4+CD25− T cells transplanted mouse which had been administered with Reg-DCsCBA or PBS as described in Example 4, were incubated in the presence of 25 ng/mL of phorbol-12-myristic acid 13-acetate (PMA) (Sigma Chemical Co.) and 1 μg/mL of ionomycin (Sigma Chemical Co.) for 72 hours. The IL-6, interferon-γ (IFN-γ), tumor necrosis factor α (TNF-α) and monocyte chemotactic protein-1 (MCP-1) in the supernatant were measured using the Cytometric Bead Array Kit (BD Biosciences Pharmingen) in accordance with the manufacturer's protocol. The IL-17 in the supernatant was measured using the ELISA kit (R&D Systems Company).
(4) Results
The results are shown in
In order to examine induction of Foxp3+CD4+CD25+ regulatory T cells and of IL-10-producing CD4+CD25+ T cells from Foxp3BCD4+CD25− T cells by the Reg-DCsCB in the periphery in vivo, each number of induced Foxp3+CD4+CD25+ regulatory T cells and induced IL-10-producing CD4+CD25+ T cells was counted according to the following procedure.
(1) Preparation of Mouse and MLN
The CD4+CD25− T cells transplanted mouse was administered with Reg-DCsCBA or PBS as described in Example 4, and MLN cells were taken from said mouse at 1, 3 and 5 week(s) after the CD4+CD25− T cells transplantation and then incubated in 200 μL of RPMI1640 medium in the presence of 25 ng/mL of PMA (Sigma Chemical Co.) and 1 μg/mL of ionomycin (Sigma Chemical Co.) for 72 hours.
(2) Measurement of Foxp3+CD4+CD25+Regulatory T Cells
To examine a proportion of Foxp3+CD4+CD25+ regulatory T cells in the MLN, the MLN was taken at 1, 3 and 5 week(s) after the CD4+CD25− T cells transplantation and incubated in 200 μL of RPMI1640 medium in the presence of 25 ng/mL of PMA (Sigma Chemical Co.) and 1 μg/mL of ionomycin (Sigma Chemical Co.) in a round-bottom 96-well plate for 72 hours. Then, the cultured cells were stained with PE labeled anti-Foxp3 monoclonal antibody, APC labeled anti-CD25 monoclonal antibody and PerCP labeled anti-CD4 monoclonal antibody in accordance with the recommended protocol by the Manufacturer. The fluorescence staining was examined by flow cytometry analysis.
(3) Measurement of IL-10-producing CD4+CD25+ Regulatory T Cells
To examine a proportion of IL-10-producing CD4+CD25+ regulatory T cells in the MLN, the MLN was taken at 2, 4, 7 and 14 days after CD4+CD25− T cells transplantation and incubated in 200 μL of RPMI1640 medium in the presence of 25 ng/mL of PMA (Sigma Chemical Co.) and 1 μg/mL of ionomycin (Sigma Chemical Co.) in a round-bottom 96-well plate for 24 hours. For the last 3 hours incubation, GolgiStop (BD Pharmingen) was added thereto. Then, the cells were incubated with PerCP labeled anti-CD4 monoclonal antibody and APC labeled anti-CD25 monoclonal antibody in a dark room at room temperature for 15 minutes, and then, fixed and permeabilized with FIX & PERM Kit (Caltag Laboratories Inc., Burlingame, Calif., US). The resulting cells were stained with PE labeled rat anti-mouse IL-10 monoclonal antibody (Clone JES5-16E3, D Pharmingen) at room temperature for 20 minutes. The fluorescence staining was examined by flow cytometry analysis.
(4) Results
The results are shown in
CBA was prepared as described in Example 4.
Prior to the isoelectric focusing electrophoresis, the CBA sample was treated with 2-D Clean-Up Kit (GE Healthcare Bioscience Co., Ltd., Piscataway, N.J., US). The resulting pellet was resuspended into buffered solution (30 mM of Tris-HCl, pH 8.5, containing 7 M urea, 2 M thiourea, 4% CHAPS and PlusOne Protease Inhibitor Mix). The sample was dissolved into swelling buffer solution (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer, pH 3 to 10, and 1% DTT) and was swollen with the 24 cm of Immobiline DryStrip, pH 3 to 10 (GE Healthcare Bioscience Co., Ltd.) at 20° C. for 10 hours. The isoelectric focusing electrophoresis was carried out with IPGphor II at 20° C. for a total of 45 kVh. Next, the resulting IPG gel was equilibrated with 50 mM Tris-HCl, pH 8.8, containing 6 M urea, 30% glycerol, 2% SDS, 0.002% of bromophenol blue and 0.5% DTT for 15 minutes. And then, it was alkylated in buffer solution containing 50 mM of Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 0.002% bromophenol blue and 4.5% iodoacetamide for 15 minutes. Soon after that, the resulting strip was applied onto the 12.5% SDS-PAGE gel and electrophoresed with EttanDALTsix electrophoresis system (GE Healthcare Bioscience Co., Ltd.) under a condition of 2 W at 30° C. for 16 hours. The gel was stained with Deep Purple Total Protein Stain (GE Healthcare Bioscience Co., Ltd.) according to the standard protocol. The stained gel was scanned with Ettan DIGE Imager (GE Healthcare Bioscience Co., Ltd.), and the resulting image was analyzed with ImageMaster 2D Platinum (GE Healthcare Bioscience Co., Ltd.). Each spot was quantified based on its relative volume (a spot volume divided by the total volume of all gel spots).
(3) Mass Spectrometry
A protein spot was cut from the gel, washed, and digested by pig trypsin protease in the gel. The trypsin peptide was extracted by sonication. Using nano LC-AccuSpot (Shimadzu Corporation, Kyoto, Japan), HPLC and MALDI samples were prepared and spotted onto μ FOCUS MALDI plate (Shimadzu Corporation). The tandem TOF/TOF mass spectrometry was performed with Axima-TOF2 mass spectrometer (Shimadzu Corporation). The protein was identified by “MASCOT” MS/MS ion search engine (Matrix Science, London, UK) and the protein database provided by National Center for Biotechnology Information.
The results are shown in
Colons taken from SCID mouse which was not administered with CD4+CD25− T cells, SCID mouse with enteritis induced by the CD4+CD25− T cells as described in Example 4, and an SCID mouse which was administered with both of the CD4+CD25− T cells and Reg-DCsCBA were examined to determine CA I expression by immunohistochemical staining.
A 5 μm frozen tissue section of the colon was fixed with acetone. The section was treated with method containing 1% hydrogen peroxide for 20 minutes and then with PBS containing 0.1% Tween-20 for 10 minutes to inactivate endogenous peroxidase activity. The tissue section was inactivated with endogenous avidin/biotin blocking kit (Nichirei Corporation, Tokyo, Japan) pretreated with Rabbit Serum (Nichirei Corporation), followed by incubation in the presence of 1:50 diluted biotinylated goat anti-human CA I antibody (Rockland Immunochemicals Inc., Philadelphia, Pa., US) at 4° C. overnight. Then, the tissue section was treated with horseradish-conjugated streptavidin (Nichirei Corporation), followed by incubation with Simple Stain DAB solution (Nichirei Corporation). Finally, the tissue section was counterstained with hematoxylin and dried to prepare a sample.
(2) Results
The results are shown in
To examine whether the CA I-pulsed regulatory dendritic cells improves enteritis of the CD4+CD25− T cell-transplanted inflammatory bowel disease model mouse, CA I-pulsed regulatory dendritic cells were administered to the mouse which was administered with CD4+CD25− T cells and the effect was evaluated.
The mouse CA I was prepared by cell free protein synthesis system using wheat germ ribosomal RNA (K. Madin et al., Proc. Natl. Acad. Sci. USA, 97: 559-64 (2000)), which have no risk of contamination of LPS. The expression plasmid (pEU-mCA1-His) was prepared as follows. The mouse CA1 gene was amplified with each 0.3 μM or less of primers mCA1F and mCA1R by using KOD-Plus-Ver. 2 kit (Toyobo Co., Ltd., Osaka, Japan).
The CA I was synthesized with Robotic Protein Synthesizer (trademark) DT (Cellfree Science Co., Ltd., Matsuyama, Japan) in accordance with the manufacturer's protocol as previously reported (T. Sawasaki et al., FEBS Lett., 514: 102-5 (2002)). The resulting His-fused CA I was purified with Ni Sepharose High Performance (GE Healthcare Bioscience Co., Ltd.). An AcTEV (trademark) protease (Invitrogen Corporation) was used to remove a His tag from the fusion protein and then the solution was dialyzed against PBS using Mini Dialysis Kit (GE Healthcare Bioscience Co., Ltd.).
Proteins prepared using the empty plasmid non-genetically recombined with CA I gene sequences by the cell free protein synthesis system in accordance with Preparation of CA I were used as CA I-control.
(2) Preparation and Pulsing of Regulatory Dendritic Cell
The regulatory dendritic cells were prepared according to the procedures described in Example 1. The prepared regulatory dendritic cells were pulsed with 6 μg/mL of CA I or CA I-control for 24 hours to produce CA I-pulsed regulatory dendritic cells (Reg-DCsCA1) or CA I-control-pulsed regulatory dendritic cells (Reg-DCsCA1-control), respectively.
(3) Preparation of Enteritis Model Mouse and Treatment with Dendritic Cell
The enteritis model mouse was prepared according to the procedures described in Example 4. 3×105 cells/mouse of the CD4+CD25− T cells taken from BALB/c mouse were administered intraperitoneally and transplanted to a B-17 SCID mouse. The transplanting date was set as day 0. The C.B-17 mice which was not administered with CD4+CD25− T cells were used as a control group (n=5). On day 0, together with the CD4+CD25− T cells, each of Reg-DCsCBA (n=7), Reg-DCsCA1-control (n=8) and Reg-DCsCA1 (n=10) taken from the BALB/c mouse was administered intraperitoneally in of 1×106 cells/mouse. The mice which were administered with PBS instead of the dendritic cells was defined as a PBS group (n=13). The mice were weighed every week. The mice were euthanized 4 weeks after the cell transplantation to determine a length of colons.
(4) Histological Evaluation of Colitis
The mouse was euthanized 4 weeks after the cell transplantation to take a colon from it. A transverse colon was extracted, fixed in 10% neutral buffered formalin and embedded in paraffin. The tissue section was stained by H&E or PAS. A degree of inflammation in the tissue section was rated according to the procedure described in Example 4.
(5) Measurement of mRNA Expression of Inflammatory Cytokine in Colon
Each mRNA expression of IL-17, IL-10 and TGF-β in the colon was measured according to the procedure described in Example 5.
(6) mRNA Expression of Transcription Factor and Inflammatory Cytokine in MLN
Each mRNA expression of IL-17, IL-10, TGF-β, Foxp3 and RORγ T in the MLN was measured according to the procedure described in Example 6.
(7) Measurement of Production Quantity of Inflammatory Cytokine in Ex Vivo Cultured Colon
The IL-6, IL-17, TNF-α and IFN-γ in the colon culture supernatant were measured according to the procedure described in Example 5.
(8) Measurement of Production Quantity of Inflammatory Cytokine in MLN Cell
The IL-6, IL-17, TNF-α, IFN-γ and MCP-1 in the culture supernatant of MLN cell were measured according to the procedure described in Example 6.
(9) Results
The results were shown in
The measurements of mRNA expression showed that in the colon and the MLN of the mouse administered with Reg-DCsCA1, IL-17A expression was decreased, whereas both expressions of IL-10 and TGF-β were increased (P<0.05) (
The analysis of the cultured supernatant of the colon showed that each production quantity of IL-17, IFN-γ and TNF-α in the colon of the mouse administered with Reg-DCsCA1 was significantly smaller than that of the mouse administered with PBS (P<0.05) (
cDNA of Mouse CA I (hereinafter referred to as mCA1) was amplified using the following primers:
The amplified DNA was inserted into a plasmid pET 45b (Merk kGaA, Darmstadt, Germany) at PshAI and BamHI sites to assemble a pET-mCA1-His6 construct expressing mCA1 tagged with 6 His at the N-terminal. The construct was confirmed by the cycle sequencing method. The His-CA1 was expressed in Escherichia coli BL21 (DE3), purified with the metal (Ni2+) affinity chromatography and then dialyzed in PBS to remove imidazole. It was further treated with EndTrap (trademark) red column (Hyglos GmbH, Regensburg, Germany) to remove endotoxin. Following SDS-PAGE, the gel was stained with Deep Purple Total Protein Stain (GE Healthcare). The gel image was analyzed by an ImageQuant TL (GE Healthcare) to calculate the purity of the protein. Control proteins prepared using the empty plasmid pET 45b in the same way as the mCA1 was used as a CAI-control.
(2) Antigen and Administration Regimen
In order to evaluate improvement of enteritis by oral administration of mCA1 to the CD4+CD25− T cell-transplanted enteritis model mouse, the C.B-17 SCID mouse was continuously fed solution of 0.6% mCA1 as drinking water for 5 days (from the day −7 to the day −2) according to the previous report (A. M. Faria et al., J. Autoimmun., 20: 135-45 (2003)). The mice were individually contained in cages and consumed 4.5±0.5 mL/day of the solution of mCA1, and an average consumption per group was 5.0±0.5 mL/day. Total dose of mCA1 per day was calculated based on the average consumption (5 mL/day). A feeding bottle containing the solution of mCA1 in PBS was changed twice a day to avoid contamination. This continuous feeding was continued for 5 days. To the control group, either PBS or CA I-control was administrated for 5 days. Seven days after the oral administration of mCA1 (day 0), CD4+CD25− T cells (3×105 cells/mouse) were intraperitoneally administered into the SCID mice.
(3) Evaluation
Measurement of body weight and colon length of the mice, histological evaluation of colitis, measurement of mRNA expression of inflammatory cytokine in colon, mRNA expression of transcription factor and inflammatory cytokine in MLN cells, measurement of production quantity of inflammatory cytokine in the ex vivo cultured colon, and measurement of production quantity of inflammatory cytokine in MLN cells were carried out as described in Example 10.
(4) Results
The oral administration of CA I improved enteritis of the CD4+CD25− T cell-transplanted inflammatory bowel disease model mouse. At 4 weeks after the cell transplantation, body weight of the mouse administered with mCA1 was significantly increased compared with the mouse administered with PBS (P<0.05) (
The inflammatory bowel disease model mouse administered with mCA1 expressed significantly increased level of mRNA of IL-10 in colon compared with the mouse administered with PBS (P<0.05) (
The measurement results of the cytokine production in the tissue section of the colon and in the MLN cells taken from the inflammatory bowel disease model mice which were administered with PBS or mCA1 showed that the mouse administered with mCA1 produced significantly decreased quantities of IL-6 and MCP-1 in colon compared with the mouse administered with PBS (P<0.05) (
These results suggest that CBA-pulsed regulatory dendritic cell inhibits progress of enteritis of CD4+CD25− T cells-transplanted enteritis model mouse; CA I, a primary antigen of CBA, plays an important role in suppression of development of colitis by the regulatory dendritic cells; the CA I-pulsed regulatory dendritic cells induces the Foxp3+ regulatory T cells in MLN and to decreases T-helper-17 cells; and the CBA-pulsed regulatory dendritic cells induces the Foxp3+CD4+CD25+ T cells and IL-10-producing CD4+CD25+ T cells in vivo. The results of the present experiments also show that the treatment with Reg-DCsCBA improves clinical and histopathological severity of enteritis. Further, the results show that only CBA pulsed regulatory dendritic cells suppresses enteritis, but not KLH pulsed regulatory dendritic cells. Furthermore, a primary protein of CBA is identified as CA I. Therefore, from these findings it has been showed that the regulatory dendritic cells antigen-specifically inhibits enteritis, and that both of CBA and its primary antigen CA I can be the principal targets for inflammatory bowel disease. In this experiment, the significantly decreased CA I expression in the CD4+CD25− T cell-transplanted enteritis was maintained by administration of Reg-DCsCBA. Also, Reg-DCsCA1 has been shown to have depressant effect on enteritis in the enteritis model mouse. Therefore, it has been shown that CA I is the antigen specific to the inflammatory bowel disease. In addition, the oral administration of CA I exerts depressant effect on enteritis in inflammatory bowel disease model mouse. This result also supports that CA I is the antigen specific to the inflammatory bowel disease.
Accordingly, from these results, it has been revealed that CA I-pulsed regulatory dendritic cells control the balance between Foxp3+CD4+CD25+ T cells and Th17 cells and thus inhibit the progress of CD4+CD25− T cells-transplanted enteritis. This suggests that the cell therapy by the CA I-pulsed regulatory dendritic cells can be a novel method for treating inflammatory bowel disease. Further, this also suggests that CA I can be a therapeutic agent or a preventive agent for inflammatory bowel disease.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2009-242491 | Oct 2009 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2010/006018 | 10/7/2010 | WO | 00 | 4/20/2012 |
